Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark.
+ 2 more risks
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Saniona's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 30S's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 30S underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 30S underperformed the German Market which returned -20.6% over the past year.
Price Volatility Vs. Market
How volatile is Saniona's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Saniona undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 30S (€1.93) is trading below our estimate of fair value (€9.33)
Significantly Below Fair Value: 30S is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 30S is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 30S is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 30S's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 30S is overvalued based on its PB Ratio (10.4x) compared to the DE Biotechs industry average (3.4x).
How is Saniona forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 30S is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 30S is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 30S is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 30S's revenue (52.3% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: 30S's revenue (52.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 30S's Return on Equity is forecast to be high in 3 years time
How has Saniona performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 30S is currently unprofitable.
Growing Profit Margin: 30S is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 30S is unprofitable, and losses have increased over the past 5 years at a rate of -40.4% per year.
Accelerating Growth: Unable to compare 30S's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 30S is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 30S has a negative Return on Equity (-129.69%), as it is currently unprofitable.
How is Saniona's financial position?
Financial Position Analysis
Short Term Liabilities: 30S's short term assets (SEK53.9M) exceed its short term liabilities (SEK35.4M).
Long Term Liabilities: 30S's short term assets (SEK53.9M) exceed its long term liabilities (SEK2.1M).
Debt to Equity History and Analysis
Debt Level: 30S is debt free.
Reducing Debt: 30S had no debt 5 years ago.
Inventory Level: 30S has a low level of unsold assets or inventory.
Debt Coverage by Assets: 30S's debt is not covered by short term assets (assets are -39.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 30S has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 30S has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36.8% each year
What is Saniona's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 30S's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 30S's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 30S's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 30S's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 30S's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jørgen Drejer (64yo)
Mr. Jørgen Drejer, Ph.D., serves as Deputy Chief Executive Officer at Saniona AB (publ) since March 24, 2020 and also serves as its Chief Scientific Officer. He founded Saniona AB (Alternate name-Aniona) i ...
CEO Compensation Analysis
Compensation vs Market: Jørgen's total compensation ($USD165.74K) is below average for companies of similar size in the German market ($USD431.53K).
Compensation vs Earnings: Jørgen's compensation has increased whilst the company is unprofitable.
|Co-Founder & Director||6.25yrs||no data||2.5% SEK1.4m|
|President & CEO||0.25yr||no data||no data|
|Interim CFO & Head of Investor Relations||0.083yr||no data||no data|
|Vice President of Operations and Director of In Vivo Pharmacology||4.08yrs||no data||no data|
Experienced Management: 30S's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
|Co-Founder & Director||6.25yrs||no data||2.5% SEK1.4m|
|Chairman of the Board||2.25yrs||kr1.15m||no data|
|Independent Director||4.58yrs||kr145.00k||no data|
|Director||0.92yr||no data||no data|
|Independent Director||2.25yrs||kr184.00k||no data|
Experienced Board: 30S's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
Saniona AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Saniona AB (publ)
- Ticker: 30S
- Exchange: DB
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr629.428m
- Listing Market Cap: kr57.317m
- Shares outstanding: 29.41m
- Website: https://www.saniona.com
Number of Employees
- Saniona AB (publ)
- Baltorpvej 154
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SANION||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Apr 2014|
|0RQJ||LSE (London Stock Exchange)||Yes||Share Capital||GB||SEK||Apr 2014|
|30S||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Apr 2014|
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company’s products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson’s diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 22:59|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.